The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer
(SCLC) is slow. Extensive-stage SCLC (ES-SCLC) is a serious threat to human health, with …

Purpose The first aim of the trial is to study feasibility of combined programmed death protein
ligand 1/cytotoxic T-lymphocyte-associated protein 4 inhibition concomitant to radiotherapy …

Progress in the treatment of small cell lung cancer (SCLC) has been modest over the past
decades until the advent of immune checkpoint inhibitors, which have redefined the …

Introduction The real-world data evaluating treatment outcomes of atezolizumab plus
carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are …

​ Background Immunotherapy for lung cancer has been a hot research area for years. This
bibliometric analysis aims to present the research trends on lung cancer immunotherapy …

Objectives: Small-cell lung cancer (SCLC) is a lung malignancy with high relapse rates and
poor survival outcomes. Treatment-resistant disease relapse occurs frequently and effective …

Small cell lung cancer (SCLC) is a refractory cancer with poor prognosis due to its
aggressive malignancy and high rates of metastasis, recurrence and drug resistance. These …

Opinion statement Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable
disease. However, most patients develop disease relapse shortly after definitive treatment …